Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.

Avalon GloboCare Corp.

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Alice Schwartz

David Schwartz

Bio-Rad Laboratories, Inc.

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Eduard Fresenius

Fresenius Medical Care AG & Co. KGaA

HCA Healthcare, Inc., through its subsidiaries, provides health care services company in the United States. The company operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. It also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, the company operates psychiatric hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. As of December 31, 2021, it operated 182 hospitals, including 175 general and acute care hospitals, five psychiatric hospitals, and two rehabilitation hospitals; 125 freestanding surgery centers; and 21 freestanding endoscopy centers in 20 states and England. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.

Jack C. Massey

Thomas F. Frist Sr

Thomas F. Frist III

Thomas F. Frist Jr.

HCA Healthcare, Inc.

Avalon GloboCare Corp. is a commercial-stage company engaged in developing and delivering precision diagnostics and clinical laboratory services. self-described as advancing laboratory services.

Metric
Company Name	Avalon GloboCare Corp.	Bio-Rad Laboratories, Inc.	Fresenius Medical Care AG & Co. KGaA	HCA Healthcare, Inc.
Symbol	AVCO	BIO	FME	HCA
MSH ID	COM:AVALON-GLOBOCARE	COM:BIO-RAD	COM:FRESENIUSMEDICALCARE	COM:HCAHEALTHCARE
Market	STOCKS	STOCKS	STOCKS	STOCKS
Sector	Real Estate	Healthcare	Healthcare	Healthcare
Industry	Real Estate - Services	Medical - Devices	Medical - Care Facilities	Medical - Care Facilities
Country	US	US	DE	US
Stage	Post-IPO
Employee Count	5	8K	117.13K	220K
Website	avalon-globocare.com	bio-rad.com	freseniusmedicalcare.com	hcahealthcare.com
LinkedIn		bio-rad	fresenius-medical-care-italia-spa	hca
Founders

Metric
Market Cap	5.26M	8.01B	11.22B	82.59B
Enterprise Value
Monthly Web Traffic	88
Web Traffic Growth	-0.85
Valuation
Raised Capital	20M

Metric
Revenue	2.67B	20.55B	64.97B
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.43B	5.20B	55.07B
EBITDA	576.20M	3.63B	12.73B
Operating Income	383.80M	1.58B	9.63B
Net Income	-637.32M	527.06M	5.24B
EPS	-21.82	1.80	19.25
Diluted EPS	-21.82	1.80	18.97
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.54	0.25	0.85
Operating Profit Margin	0.15	0.08	0.15
EBITDA Margin	0.22	0.18	0.20
Net Profit Margin	-0.12	0.03	0.08
Return on Equity	-0.04	0.04	-2.32
Return on Assets	-0.03	0.02	0.10
Return on Capital Employed	0.04	0.06	0.24

COM:AVALON-GLOBOCARE

Avalon GloboCare Corp.

Last Close

0.63

10/11 05:00

Market Cap

5.26M

Beta: -

Volume Today

432.17K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-58.35	19.14	14.82
P/B Ratio	1.10	0.75	-34.20
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.81	0.63	1.57
EV Multiple	16.32	0.95	4.87

Metric
Days Sales Outstanding	61.37	69.66	53.06
Days Payables Outstanding	77.12	21.21	154.99
Days Inventory Outstanding	248.85	56.09	74.50
Operating Cycle	313.70	132.45	130.49
Cash Conversion Cycle	274.47	112.72	31.13
Asset Turnover	0.26	0.62	1.19

Metric
Operating Cash Flow	374.94M	2.78B	9.43B
Free Cash Flow	218.26M	2.05B	4.69B
Cash Flow to Debt	0.30	0.34	0.25
Operating Cash Flow/Sales	0.14	0.16	0.15
Free Cash Flow Yield	0.02	0.16	0.05

Metric
Cash & Equivalents	403.97M	1.48B	935M
Accounts Receivable	11.40M	-160.38M	-935M
Inventory	780.52M	2.30B	2.02B
Goodwill	413.60M	15.47B	9.61B
Debt to Capitalization	0.15	0.47	1.05
Debt to Assets	0.10	0.36	0.75
Current Ratio	5.64	1.37	1.15
Quick Ratio	4.89	1.14	0.94

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.02	-0.02	0.00
R&D to Revenue	0.09	0.01
SG&A to Revenue			0.46